Coronary interventions

High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study

EuroIntervention 2015;10:1187-1194 published online ahead of print May 2014. DOI: 10.4244/EIJY14M05_11

David Austin
David Austin1, MD, MRCP; Daniel F. Mackay2, PhD; Robert Morley1, BSc; James Christie3, BSc; Barry Hennigan3, MD; Mark A. de Belder1, MD, FRCP; Jill P. Pell2, MD, FESC; Keith G. Oldroyd3*, MD, FRCP, FSCAI
1. The James Cook University Hospital, Middlesbrough, United Kingdom; 2. Section of Public Health and Health Policy, University of Glasgow, Glasgow, United Kingdom; 3. West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Gl

Aims: The objective of this study was to analyse the outcomes of patients treated with high-bolus dose (HBD) tirofiban compared with abciximab at the time of primary PCI (PPCI) for ST-ele

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

antiplatelet treatmentcoronary artery diseaseprimary pcist-elevation myocardial infarction
Read next article
Feasibility and early safety of hybrid coronary revascularisation combining off-pump coronary surgery through J-hemisternotomy with percutaneous coronary intervention

Latest news